 John Kinsella
Concepts (572)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nitric Oxide | 83 | 2022 | 869 | 8.470 |
Why?
| | Hernias, Diaphragmatic, Congenital | 23 | 2022 | 176 | 6.880 |
Why?
| | Persistent Fetal Circulation Syndrome | 36 | 2022 | 132 | 5.070 |
Why?
| | Respiratory Insufficiency | 27 | 2022 | 293 | 3.770 |
Why?
| | Hypertension, Pulmonary | 43 | 2022 | 1703 | 3.580 |
Why?
| | Extracorporeal Membrane Oxygenation | 27 | 2022 | 216 | 3.500 |
Why?
| | Administration, Inhalation | 67 | 2022 | 656 | 2.570 |
Why?
| | Bronchopulmonary Dysplasia | 14 | 2019 | 320 | 2.430 |
Why?
| | Infant, Newborn | 99 | 2022 | 5230 | 2.390 |
Why?
| | High-Frequency Ventilation | 19 | 2006 | 42 | 2.050 |
Why?
| | Infant, Premature | 28 | 2021 | 481 | 1.980 |
Why?
| | Respiratory Distress Syndrome, Newborn | 13 | 2011 | 100 | 1.940 |
Why?
| | Bronchodilator Agents | 11 | 2020 | 273 | 1.940 |
Why?
| | Vasodilator Agents | 15 | 2022 | 335 | 1.910 |
Why?
| | Hemodynamics | 37 | 2022 | 1085 | 1.850 |
Why?
| | Oxygen Inhalation Therapy | 9 | 2015 | 147 | 1.800 |
Why?
| | Hernia, Diaphragmatic | 9 | 2021 | 71 | 1.630 |
Why?
| | Pulmonary Circulation | 29 | 2006 | 443 | 1.540 |
Why?
| | Infant, Premature, Diseases | 6 | 2019 | 98 | 1.490 |
Why?
| | Ventricular Dysfunction, Left | 4 | 2022 | 398 | 1.380 |
Why?
| | Respiration, Artificial | 25 | 2019 | 563 | 1.310 |
Why?
| | Hypoxia | 18 | 2021 | 923 | 1.250 |
Why?
| | Vascular Resistance | 27 | 2021 | 380 | 1.050 |
Why?
| | Echocardiography | 12 | 2020 | 616 | 0.970 |
Why?
| | Transportation of Patients | 3 | 2020 | 52 | 0.940 |
Why?
| | Oxygen | 19 | 2021 | 864 | 0.930 |
Why?
| | Blood Gas Analysis | 6 | 2021 | 82 | 0.920 |
Why?
| | Humans | 148 | 2022 | 117633 | 0.890 |
Why?
| | Bronchoconstriction | 1 | 2020 | 25 | 0.810 |
Why?
| | Lung | 29 | 2022 | 3645 | 0.810 |
Why?
| | Gestational Age | 21 | 2019 | 786 | 0.780 |
Why?
| | Ventricular Dysfunction | 1 | 2019 | 17 | 0.770 |
Why?
| | Sheep | 38 | 2007 | 748 | 0.760 |
Why?
| | Pulmonary Gas Exchange | 11 | 2009 | 136 | 0.760 |
Why?
| | Heart Atria | 1 | 2020 | 124 | 0.730 |
Why?
| | Cardiovascular System | 1 | 2020 | 118 | 0.730 |
Why?
| | Fetus | 20 | 2018 | 668 | 0.720 |
Why?
| | Ductus Arteriosus, Patent | 4 | 2015 | 45 | 0.710 |
Why?
| | Pre-Eclampsia | 1 | 2020 | 151 | 0.700 |
Why?
| | Vasodilation | 18 | 2005 | 468 | 0.690 |
Why?
| | Anaphylaxis | 1 | 2020 | 144 | 0.670 |
Why?
| | Trachea | 2 | 2018 | 221 | 0.650 |
Why?
| | Infant | 31 | 2022 | 8255 | 0.640 |
Why?
| | Early Medical Intervention | 2 | 2014 | 55 | 0.630 |
Why?
| | Heart Ventricles | 3 | 2020 | 756 | 0.610 |
Why?
| | Pulmonary Surfactants | 6 | 2021 | 103 | 0.610 |
Why?
| | Intensive Care Units | 4 | 2018 | 594 | 0.600 |
Why?
| | Critical Care | 5 | 2013 | 519 | 0.600 |
Why?
| | Prenatal Diagnosis | 1 | 2018 | 176 | 0.590 |
Why?
| | Animals, Newborn | 17 | 2007 | 846 | 0.590 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2015 | 18 | 0.590 |
Why?
| | Hyaline Membrane Disease | 6 | 1998 | 21 | 0.580 |
Why?
| | Monitoring, Physiologic | 3 | 2019 | 269 | 0.580 |
Why?
| | Blood Coagulation | 1 | 2017 | 200 | 0.580 |
Why?
| | Umbilical Arteries | 1 | 2015 | 36 | 0.570 |
Why?
| | Radial Artery | 1 | 2015 | 69 | 0.550 |
Why?
| | Pulmonary Artery | 19 | 2021 | 1073 | 0.550 |
Why?
| | Severity of Illness Index | 12 | 2020 | 2884 | 0.520 |
Why?
| | Vitamin A | 1 | 2013 | 53 | 0.500 |
Why?
| | Oxygen Consumption | 3 | 2015 | 650 | 0.500 |
Why?
| | Superoxide Dismutase | 2 | 2006 | 360 | 0.490 |
Why?
| | Female | 65 | 2022 | 63247 | 0.480 |
Why?
| | Practice Guidelines as Topic | 3 | 2020 | 1524 | 0.480 |
Why?
| | Vitamins | 1 | 2013 | 164 | 0.460 |
Why?
| | Intestinal Obstruction | 1 | 2012 | 39 | 0.440 |
Why?
| | Phosphodiesterase Inhibitors | 5 | 2013 | 93 | 0.430 |
Why?
| | Male | 51 | 2020 | 60403 | 0.430 |
Why?
| | Alcohol-Related Disorders | 1 | 2013 | 120 | 0.430 |
Why?
| | Muscle, Smooth, Vascular | 8 | 2005 | 457 | 0.410 |
Why?
| | Retrospective Studies | 21 | 2022 | 12331 | 0.400 |
Why?
| | Hospital Mortality | 3 | 2018 | 853 | 0.400 |
Why?
| | Paresis | 1 | 2010 | 21 | 0.400 |
Why?
| | Lung Diseases | 6 | 2010 | 724 | 0.390 |
Why?
| | Dietary Supplements | 1 | 2013 | 465 | 0.380 |
Why?
| | Sulfones | 4 | 2013 | 103 | 0.380 |
Why?
| | Adrenal Insufficiency | 1 | 2010 | 28 | 0.380 |
Why?
| | Emergency Medicine | 1 | 2013 | 257 | 0.370 |
Why?
| | Conscious Sedation | 1 | 2010 | 79 | 0.370 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2011 | 167 | 0.370 |
Why?
| | Herniorrhaphy | 2 | 2020 | 40 | 0.360 |
Why?
| | Dipyridamole | 6 | 1998 | 27 | 0.360 |
Why?
| | Survival Rate | 13 | 2022 | 1807 | 0.350 |
Why?
| | Pacemaker, Artificial | 1 | 2009 | 111 | 0.350 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2010 | 194 | 0.350 |
Why?
| | Treatment Outcome | 23 | 2017 | 9353 | 0.350 |
Why?
| | Nose | 2 | 2008 | 56 | 0.340 |
Why?
| | Nitric Oxide Synthase | 13 | 2005 | 234 | 0.340 |
Why?
| | Heart Defects, Congenital | 7 | 2022 | 721 | 0.340 |
Why?
| | Anesthetics, Intravenous | 1 | 2008 | 34 | 0.340 |
Why?
| | Meconium Aspiration Syndrome | 3 | 2003 | 11 | 0.340 |
Why?
| | Fluorocarbons | 2 | 1999 | 86 | 0.330 |
Why?
| | Propofol | 1 | 2008 | 43 | 0.330 |
Why?
| | Foreign Bodies | 1 | 2008 | 94 | 0.310 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3214 | 0.310 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2007 | 129 | 0.310 |
Why?
| | Action Potentials | 1 | 2010 | 455 | 0.310 |
Why?
| | Cardiac Output | 7 | 2009 | 155 | 0.300 |
Why?
| | Child | 20 | 2022 | 18649 | 0.300 |
Why?
| | Piperazines | 3 | 2013 | 323 | 0.280 |
Why?
| | Animals | 54 | 2022 | 34350 | 0.280 |
Why?
| | Respiration Disorders | 1 | 2005 | 68 | 0.270 |
Why?
| | Respiration | 3 | 2019 | 196 | 0.260 |
Why?
| | Preoperative Care | 3 | 2017 | 323 | 0.250 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2013 | 1419 | 0.250 |
Why?
| | Ventricular Function, Left | 6 | 2020 | 503 | 0.250 |
Why?
| | Heart | 3 | 2019 | 655 | 0.240 |
Why?
| | Pulmonary Alveoli | 3 | 2021 | 395 | 0.240 |
Why?
| | Pregnancy | 15 | 2020 | 5554 | 0.240 |
Why?
| | Fatal Outcome | 4 | 2012 | 305 | 0.230 |
Why?
| | Nitrites | 1 | 2002 | 76 | 0.230 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2020 | 2106 | 0.230 |
Why?
| | Ductus Arteriosus | 10 | 2005 | 71 | 0.230 |
Why?
| | Infant, Very Low Birth Weight | 2 | 2017 | 69 | 0.230 |
Why?
| | Respiratory Therapy | 3 | 2003 | 19 | 0.230 |
Why?
| | Antioxidants | 1 | 2006 | 585 | 0.220 |
Why?
| | Gastroesophageal Reflux | 2 | 2022 | 246 | 0.220 |
Why?
| | Incidence | 5 | 2015 | 2504 | 0.220 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 2020 | 8 | 0.200 |
Why?
| | Emergency Treatment | 1 | 2002 | 114 | 0.200 |
Why?
| | Fundoplication | 1 | 2020 | 55 | 0.200 |
Why?
| | Vasoconstriction | 3 | 2005 | 221 | 0.200 |
Why?
| | Plethysmography | 1 | 2001 | 139 | 0.200 |
Why?
| | Papio | 6 | 1995 | 98 | 0.200 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2019 | 1209 | 0.200 |
Why?
| | Prospective Studies | 9 | 2021 | 6422 | 0.200 |
Why?
| | Carbon Monoxide | 1 | 2000 | 70 | 0.190 |
Why?
| | Patient Care Team | 2 | 2016 | 524 | 0.190 |
Why?
| | Therapy, Computer-Assisted | 1 | 2020 | 63 | 0.190 |
Why?
| | Fluid Therapy | 2 | 2011 | 151 | 0.190 |
Why?
| | Pulmonary Veins | 2 | 1999 | 84 | 0.190 |
Why?
| | Critical Illness | 3 | 2014 | 616 | 0.180 |
Why?
| | Neoplasm Staging | 3 | 2018 | 1215 | 0.180 |
Why?
| | Blood Pressure | 12 | 2014 | 1680 | 0.180 |
Why?
| | Thrombelastography | 1 | 2020 | 236 | 0.170 |
Why?
| | Treatment Failure | 5 | 2007 | 340 | 0.170 |
Why?
| | Intubation, Intratracheal | 2 | 2018 | 193 | 0.170 |
Why?
| | Biological Products | 1 | 2000 | 145 | 0.170 |
Why?
| | Cerebral Hemorrhage | 2 | 2014 | 89 | 0.170 |
Why?
| | Down Syndrome | 1 | 2022 | 329 | 0.170 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2018 | 75 | 0.170 |
Why?
| | Retinopathy of Prematurity | 1 | 2019 | 108 | 0.170 |
Why?
| | Pneumonectomy | 1 | 2019 | 121 | 0.170 |
Why?
| | Single-Blind Method | 2 | 2013 | 282 | 0.160 |
Why?
| | Risk Factors | 9 | 2020 | 9124 | 0.160 |
Why?
| | Time Factors | 11 | 2017 | 6906 | 0.160 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 177 | 0.160 |
Why?
| | Combined Modality Therapy | 6 | 2017 | 1191 | 0.160 |
Why?
| | Risk | 3 | 2021 | 926 | 0.160 |
Why?
| | Blood Coagulation Disorders | 1 | 2020 | 234 | 0.160 |
Why?
| | Dyspnea | 1 | 2018 | 199 | 0.160 |
Why?
| | Smoke Inhalation Injury | 3 | 1991 | 18 | 0.160 |
Why?
| | Methemoglobin | 2 | 1993 | 20 | 0.160 |
Why?
| | Blood Circulation | 3 | 1998 | 34 | 0.160 |
Why?
| | Emergency Service, Hospital | 1 | 2008 | 1819 | 0.150 |
Why?
| | Anesthesia, Local | 1 | 2016 | 15 | 0.150 |
Why?
| | Capillary Permeability | 1 | 1997 | 146 | 0.150 |
Why?
| | Glycocalyx | 1 | 2016 | 20 | 0.150 |
Why?
| | Infant, Newborn, Diseases | 2 | 2014 | 103 | 0.150 |
Why?
| | Pulmonary Edema | 1 | 1997 | 148 | 0.150 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2019 | 196 | 0.150 |
Why?
| | Mentors | 1 | 2018 | 156 | 0.150 |
Why?
| | Follow-Up Studies | 10 | 2019 | 4911 | 0.150 |
Why?
| | Echocardiography, Doppler | 2 | 2001 | 119 | 0.150 |
Why?
| | Receptors, Platelet-Derived Growth Factor | 1 | 1996 | 13 | 0.150 |
Why?
| | Survivors | 1 | 2019 | 423 | 0.150 |
Why?
| | Guidelines as Topic | 1 | 2018 | 281 | 0.150 |
Why?
| | Surgical Procedures, Operative | 1 | 2018 | 174 | 0.150 |
Why?
| | Child, Preschool | 13 | 2017 | 9714 | 0.150 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2015 | 12 | 0.150 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2016 | 30 | 0.140 |
Why?
| | Heart Rate | 3 | 2009 | 788 | 0.140 |
Why?
| | Cardiac Catheterization | 6 | 2022 | 561 | 0.140 |
Why?
| | Disease Management | 2 | 2017 | 603 | 0.140 |
Why?
| | Academic Medical Centers | 1 | 2018 | 414 | 0.140 |
Why?
| | Faculty, Medical | 1 | 2018 | 256 | 0.140 |
Why?
| | Respiratory Function Tests | 4 | 2019 | 596 | 0.140 |
Why?
| | Cerebrovascular Circulation | 3 | 1995 | 193 | 0.140 |
Why?
| | Chronic Disease | 8 | 2013 | 1674 | 0.140 |
Why?
| | Length of Stay | 4 | 2017 | 1046 | 0.140 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 724 | 0.140 |
Why?
| | Neutrophils | 3 | 1999 | 1263 | 0.140 |
Why?
| | United Kingdom | 2 | 2013 | 245 | 0.140 |
Why?
| | Radiography | 2 | 2008 | 860 | 0.140 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 285 | 0.140 |
Why?
| | Sildenafil Citrate | 4 | 2021 | 57 | 0.130 |
Why?
| | Mothers | 1 | 2020 | 664 | 0.130 |
Why?
| | Risk Assessment | 4 | 2017 | 3208 | 0.130 |
Why?
| | Statistics as Topic | 1 | 2015 | 333 | 0.130 |
Why?
| | Biomarkers | 4 | 2016 | 3574 | 0.130 |
Why?
| | Nitroarginine | 9 | 2005 | 49 | 0.130 |
Why?
| | Ventilator Weaning | 2 | 2005 | 32 | 0.130 |
Why?
| | Thrombosis | 1 | 2017 | 286 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2011 | 507 | 0.130 |
Why?
| | Pediatrics | 2 | 2019 | 1021 | 0.120 |
Why?
| | Vasoconstrictor Agents | 1 | 2014 | 124 | 0.120 |
Why?
| | Elective Surgical Procedures | 2 | 2011 | 146 | 0.120 |
Why?
| | Continuity of Patient Care | 1 | 2016 | 275 | 0.120 |
Why?
| | Registries | 5 | 2022 | 1969 | 0.120 |
Why?
| | Alcohol Withdrawal Delirium | 1 | 2013 | 12 | 0.120 |
Why?
| | Hemorrhage | 1 | 2017 | 605 | 0.120 |
Why?
| | Clinical Trials as Topic | 3 | 2008 | 999 | 0.120 |
Why?
| | Vasopressins | 1 | 2014 | 143 | 0.120 |
Why?
| | Hypotension | 1 | 2014 | 127 | 0.120 |
Why?
| | Anticoagulants | 1 | 2017 | 541 | 0.120 |
Why?
| | Epoprostenol | 3 | 2021 | 138 | 0.120 |
Why?
| | Critical Care Nursing | 1 | 2013 | 29 | 0.120 |
Why?
| | Coronary Circulation | 2 | 1995 | 147 | 0.120 |
Why?
| | Renal Dialysis | 1 | 2016 | 379 | 0.120 |
Why?
| | Cell Nucleus | 1 | 1996 | 588 | 0.110 |
Why?
| | Liver Cirrhosis | 1 | 2014 | 223 | 0.110 |
Why?
| | Middle Aged | 12 | 2019 | 28659 | 0.110 |
Why?
| | Estradiol | 3 | 2000 | 465 | 0.110 |
Why?
| | Vascular Diseases | 1 | 2015 | 238 | 0.110 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2011 | 8 | 0.110 |
Why?
| | Delivery Rooms | 1 | 2011 | 7 | 0.110 |
Why?
| | Early Diagnosis | 1 | 2013 | 253 | 0.110 |
Why?
| | Ventilators, Mechanical | 2 | 2016 | 48 | 0.110 |
Why?
| | Troponin | 1 | 2011 | 47 | 0.110 |
Why?
| | Prognosis | 5 | 2017 | 3549 | 0.110 |
Why?
| | Acetylcholine | 5 | 2001 | 204 | 0.110 |
Why?
| | Patient Admission | 1 | 2013 | 199 | 0.100 |
Why?
| | Postoperative Complications | 5 | 2017 | 2113 | 0.100 |
Why?
| | Aged | 10 | 2019 | 20249 | 0.100 |
Why?
| | Respiratory Mechanics | 3 | 1999 | 78 | 0.100 |
Why?
| | Double-Blind Method | 2 | 2009 | 1695 | 0.100 |
Why?
| | Case-Control Studies | 2 | 2018 | 3269 | 0.100 |
Why?
| | Delivery, Obstetric | 1 | 1991 | 118 | 0.100 |
Why?
| | Monitoring, Intraoperative | 2 | 2008 | 36 | 0.100 |
Why?
| | Cardiac Output, Low | 1 | 1991 | 78 | 0.100 |
Why?
| | Diseases in Twins | 1 | 2012 | 208 | 0.100 |
Why?
| | Infusions, Intravenous | 2 | 2009 | 393 | 0.100 |
Why?
| | Disease Models, Animal | 7 | 2007 | 3799 | 0.100 |
Why?
| | Communication | 1 | 2016 | 731 | 0.100 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 167 | 0.100 |
Why?
| | Physicians | 1 | 2018 | 771 | 0.100 |
Why?
| | DNA-Binding Proteins | 2 | 2007 | 1384 | 0.100 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2011 | 175 | 0.100 |
Why?
| | Platelet-Derived Growth Factor | 2 | 2003 | 87 | 0.090 |
Why?
| | Thoracic Surgical Procedures | 1 | 2010 | 55 | 0.090 |
Why?
| | Death, Sudden, Cardiac | 1 | 2012 | 229 | 0.090 |
Why?
| | Abdomen | 1 | 2010 | 118 | 0.090 |
Why?
| | Endothelium, Vascular | 5 | 2016 | 928 | 0.090 |
Why?
| | Hospitalization | 1 | 2018 | 1774 | 0.090 |
Why?
| | Positive-Pressure Respiration | 2 | 2000 | 73 | 0.090 |
Why?
| | Endothelins | 3 | 2000 | 60 | 0.090 |
Why?
| | Airway Obstruction | 1 | 1991 | 167 | 0.090 |
Why?
| | Endothelin Receptor Antagonists | 3 | 1998 | 61 | 0.090 |
Why?
| | Vitamin D | 1 | 2012 | 363 | 0.090 |
Why?
| | Regional Blood Flow | 4 | 1998 | 439 | 0.090 |
Why?
| | Anesthetics, Combined | 1 | 2008 | 8 | 0.090 |
Why?
| | Nitric Oxide Synthase Type III | 6 | 2007 | 196 | 0.090 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 158 | 0.090 |
Why?
| | Logistic Models | 3 | 2020 | 2018 | 0.090 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2011 | 244 | 0.080 |
Why?
| | Neoplasms | 2 | 2019 | 2139 | 0.080 |
Why?
| | Chest Wall Oscillation | 1 | 2007 | 5 | 0.080 |
Why?
| | Patient Readmission | 1 | 2013 | 659 | 0.080 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 517 | 0.080 |
Why?
| | Receptors, Endothelin | 3 | 2000 | 51 | 0.080 |
Why?
| | Lung Neoplasms | 2 | 2019 | 2171 | 0.080 |
Why?
| | Acute Disease | 2 | 2005 | 983 | 0.080 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 2 | 1998 | 18 | 0.080 |
Why?
| | Hydrocortisone | 1 | 2010 | 332 | 0.080 |
Why?
| | Transcription Factors | 1 | 1996 | 1623 | 0.080 |
Why?
| | Sex Distribution | 1 | 2008 | 390 | 0.080 |
Why?
| | Microspheres | 3 | 1991 | 99 | 0.080 |
Why?
| | Leukomalacia, Periventricular | 1 | 2006 | 8 | 0.080 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2004 | 104 | 0.080 |
Why?
| | Purines | 3 | 2013 | 166 | 0.080 |
Why?
| | Survival Analysis | 2 | 2009 | 1358 | 0.080 |
Why?
| | Piperidines | 1 | 2008 | 174 | 0.080 |
Why?
| | Analysis of Variance | 5 | 2014 | 1451 | 0.070 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2010 | 846 | 0.070 |
Why?
| | Pilot Projects | 4 | 2016 | 1441 | 0.070 |
Why?
| | Intracranial Hemorrhages | 1 | 2006 | 71 | 0.070 |
Why?
| | Cross-Over Studies | 2 | 1998 | 499 | 0.070 |
Why?
| | Endothelin-1 | 5 | 2000 | 169 | 0.070 |
Why?
| | Swine | 2 | 2003 | 734 | 0.070 |
Why?
| | Atrial Natriuretic Factor | 2 | 1996 | 64 | 0.070 |
Why?
| | Lung Compliance | 1 | 2005 | 53 | 0.070 |
Why?
| | Airway Resistance | 1 | 2005 | 35 | 0.070 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2005 | 41 | 0.070 |
Why?
| | Electroencephalography | 1 | 2008 | 466 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 235 | 0.070 |
Why?
| | Signal Transduction | 3 | 2005 | 4824 | 0.070 |
Why?
| | Longitudinal Studies | 2 | 2006 | 2668 | 0.070 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2007 | 232 | 0.070 |
Why?
| | Adult | 9 | 2014 | 32118 | 0.070 |
Why?
| | Enzyme Inhibitors | 7 | 2005 | 874 | 0.070 |
Why?
| | Amides | 1 | 2005 | 87 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 1971 | 0.070 |
Why?
| | Pulmonary Wedge Pressure | 2 | 2022 | 74 | 0.070 |
Why?
| | Carbon Dioxide | 4 | 1999 | 235 | 0.060 |
Why?
| | Carcinoma | 2 | 2016 | 205 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1228 | 0.060 |
Why?
| | Home Nursing | 1 | 2003 | 29 | 0.060 |
Why?
| | Colorectal Neoplasms | 1 | 2010 | 624 | 0.060 |
Why?
| | Cost-Benefit Analysis | 3 | 2011 | 553 | 0.060 |
Why?
| | Bronchoalveolar Lavage | 1 | 2003 | 93 | 0.060 |
Why?
| | Coronary Artery Bypass | 1 | 2005 | 262 | 0.060 |
Why?
| | Cyclic GMP | 3 | 1999 | 110 | 0.060 |
Why?
| | Birth Weight | 1 | 2006 | 451 | 0.060 |
Why?
| | Esophagus | 1 | 2005 | 239 | 0.060 |
Why?
| | Thyroid Neoplasms | 2 | 2016 | 240 | 0.060 |
Why?
| | Endothelial Growth Factors | 1 | 2002 | 57 | 0.060 |
Why?
| | Cohort Studies | 3 | 2022 | 5112 | 0.060 |
Why?
| | Lymphokines | 1 | 2002 | 125 | 0.060 |
Why?
| | Embryonic and Fetal Development | 3 | 2000 | 96 | 0.060 |
Why?
| | Intermittent Positive-Pressure Ventilation | 2 | 1993 | 11 | 0.060 |
Why?
| | Mosaicism | 1 | 2022 | 55 | 0.060 |
Why?
| | Mouth Mucosa | 1 | 2022 | 84 | 0.060 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 4630 | 0.060 |
Why?
| | Forced Expiratory Volume | 2 | 2016 | 599 | 0.060 |
Why?
| | Sequence Deletion | 1 | 2022 | 180 | 0.060 |
Why?
| | Evaluation Studies as Topic | 2 | 1992 | 207 | 0.050 |
Why?
| | Recombinant Proteins | 1 | 2005 | 1322 | 0.050 |
Why?
| | Forkhead Transcription Factors | 1 | 2022 | 184 | 0.050 |
Why?
| | Uterus | 1 | 2002 | 193 | 0.050 |
Why?
| | Milrinone | 1 | 2021 | 30 | 0.050 |
Why?
| | Diaphragm | 1 | 2020 | 42 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2002 | 347 | 0.050 |
Why?
| | Labor, Obstetric | 1 | 2001 | 54 | 0.050 |
Why?
| | Ligation | 5 | 2002 | 83 | 0.050 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 4842 | 0.050 |
Why?
| | Calibration | 1 | 2001 | 137 | 0.050 |
Why?
| | Injections, Intra-Arterial | 1 | 2000 | 21 | 0.050 |
Why?
| | Protoporphyrins | 1 | 2000 | 17 | 0.050 |
Why?
| | Patient Transfer | 1 | 2002 | 161 | 0.050 |
Why?
| | Hydrocarbons, Brominated | 1 | 1999 | 5 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2019 | 73 | 0.050 |
Why?
| | Inflammation | 1 | 2010 | 2538 | 0.050 |
Why?
| | Postoperative Period | 2 | 2016 | 307 | 0.050 |
Why?
| | Potassium Channel Blockers | 1 | 1999 | 42 | 0.050 |
Why?
| | Scotland | 1 | 2018 | 14 | 0.040 |
Why?
| | Constriction, Pathologic | 1 | 1999 | 206 | 0.040 |
Why?
| | Angiography | 1 | 1999 | 166 | 0.040 |
Why?
| | Drug Synergism | 2 | 1998 | 349 | 0.040 |
Why?
| | Leukocyte Count | 2 | 1997 | 328 | 0.040 |
Why?
| | Asphyxia Neonatorum | 1 | 1998 | 16 | 0.040 |
Why?
| | Blood Vessels | 1 | 2000 | 192 | 0.040 |
Why?
| | Body Weight | 2 | 2005 | 990 | 0.040 |
Why?
| | Rats | 4 | 2005 | 6016 | 0.040 |
Why?
| | Frontal Bone | 1 | 1997 | 13 | 0.040 |
Why?
| | Receptor, Endothelin A | 4 | 2000 | 59 | 0.040 |
Why?
| | Cephalometry | 1 | 1997 | 31 | 0.040 |
Why?
| | Occipital Bone | 1 | 1997 | 20 | 0.040 |
Why?
| | Disease Progression | 2 | 2017 | 2541 | 0.040 |
Why?
| | Immunohistochemistry | 4 | 2005 | 1756 | 0.040 |
Why?
| | Growth | 1 | 1997 | 60 | 0.040 |
Why?
| | Arterial Pressure | 1 | 2017 | 102 | 0.040 |
Why?
| | Blood Pressure Determination | 1 | 2017 | 130 | 0.040 |
Why?
| | Syndecan-1 | 1 | 2016 | 26 | 0.040 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2016 | 23 | 0.040 |
Why?
| | Ventricular Function, Right | 1 | 2019 | 235 | 0.040 |
Why?
| | Expectorants | 1 | 2016 | 21 | 0.040 |
Why?
| | Gastrostomy | 1 | 1997 | 89 | 0.040 |
Why?
| | Interrupted Time Series Analysis | 1 | 2016 | 38 | 0.040 |
Why?
| | Arginine | 2 | 1994 | 257 | 0.040 |
Why?
| | Endothelin-3 | 1 | 1996 | 3 | 0.040 |
Why?
| | Arteriovenous Fistula | 1 | 2016 | 23 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1997 | 187 | 0.040 |
Why?
| | Body Height | 1 | 1997 | 176 | 0.040 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 2016 | 20 | 0.040 |
Why?
| | Vascular Patency | 1 | 2016 | 88 | 0.040 |
Why?
| | Ireland | 1 | 2016 | 26 | 0.040 |
Why?
| | Interferon-Stimulated Gene Factor 3 | 1 | 1996 | 1 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 1996 | 35 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2017 | 250 | 0.040 |
Why?
| | Lung Injury | 2 | 2011 | 211 | 0.040 |
Why?
| | Thyroidectomy | 1 | 2016 | 49 | 0.040 |
Why?
| | Patient Selection | 1 | 2000 | 698 | 0.040 |
Why?
| | Enteral Nutrition | 1 | 1997 | 161 | 0.040 |
Why?
| | Substance Withdrawal Syndrome | 1 | 1998 | 185 | 0.040 |
Why?
| | Luciferases | 1 | 1996 | 148 | 0.040 |
Why?
| | Stroke Volume | 1 | 2019 | 551 | 0.040 |
Why?
| | Steroids | 1 | 2016 | 143 | 0.040 |
Why?
| | Algorithms | 2 | 2000 | 1550 | 0.040 |
Why?
| | Genetic Counseling | 1 | 2015 | 65 | 0.030 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2015 | 46 | 0.030 |
Why?
| | Blotting, Northern | 3 | 2000 | 195 | 0.030 |
Why?
| | Prostaglandins | 1 | 1995 | 85 | 0.030 |
Why?
| | Indiana | 1 | 2015 | 26 | 0.030 |
Why?
| | Tracheostomy | 1 | 2016 | 92 | 0.030 |
Why?
| | Genes, Reporter | 1 | 1996 | 282 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1405 | 0.030 |
Why?
| | Tyrosine | 1 | 1996 | 239 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 3 | 2001 | 176 | 0.030 |
Why?
| | Age Factors | 2 | 2000 | 3223 | 0.030 |
Why?
| | Aorta | 4 | 1998 | 425 | 0.030 |
Why?
| | Peptides, Cyclic | 4 | 1998 | 264 | 0.030 |
Why?
| | Organ Dysfunction Scores | 1 | 2014 | 33 | 0.030 |
Why?
| | Endothelium | 1 | 1995 | 122 | 0.030 |
Why?
| | Cardiovascular Agents | 1 | 2015 | 140 | 0.030 |
Why?
| | Drug Administration Schedule | 2 | 2011 | 780 | 0.030 |
Why?
| | Costs and Cost Analysis | 2 | 2009 | 200 | 0.030 |
Why?
| | Vasomotor System | 3 | 2002 | 50 | 0.030 |
Why?
| | Infant, Low Birth Weight | 1 | 2015 | 128 | 0.030 |
Why?
| | Life Support Care | 1 | 2014 | 27 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 1997 | 339 | 0.030 |
Why?
| | Base Sequence | 2 | 1996 | 2171 | 0.030 |
Why?
| | Primary Prevention | 1 | 2016 | 218 | 0.030 |
Why?
| | Blood Flow Velocity | 2 | 1992 | 377 | 0.030 |
Why?
| | Young Adult | 1 | 2009 | 11077 | 0.030 |
Why?
| | Schools, Medical | 1 | 2015 | 153 | 0.030 |
Why?
| | Drug Evaluation | 1 | 1993 | 85 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 1996 | 371 | 0.030 |
Why?
| | Area Under Curve | 1 | 2014 | 314 | 0.030 |
Why?
| | United States | 3 | 2012 | 12768 | 0.030 |
Why?
| | Lung Transplantation | 1 | 2015 | 304 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 292 | 0.030 |
Why?
| | Reference Values | 3 | 2002 | 835 | 0.030 |
Why?
| | Prevalence | 1 | 2019 | 2438 | 0.030 |
Why?
| | Acute Lung Injury | 1 | 2016 | 310 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 1997 | 455 | 0.030 |
Why?
| | Precision Medicine | 1 | 2016 | 291 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 1996 | 2898 | 0.030 |
Why?
| | Hypertension | 1 | 2002 | 1202 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 1996 | 672 | 0.030 |
Why?
| | ROC Curve | 1 | 2014 | 499 | 0.030 |
Why?
| | Lactic Acid | 1 | 2014 | 282 | 0.030 |
Why?
| | Decision Making | 1 | 2019 | 806 | 0.030 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2012 | 69 | 0.030 |
Why?
| | Streptococcus agalactiae | 1 | 1993 | 84 | 0.030 |
Why?
| | Brain Chemistry | 1 | 1992 | 148 | 0.030 |
Why?
| | Asthma | 1 | 2005 | 2016 | 0.030 |
Why?
| | Child Development | 1 | 1997 | 470 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2016 | 6795 | 0.030 |
Why?
| | Liver | 1 | 2020 | 1856 | 0.030 |
Why?
| | Isotonic Solutions | 1 | 2011 | 45 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 1995 | 326 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2012 | 185 | 0.030 |
Why?
| | Brain | 2 | 1997 | 2699 | 0.030 |
Why?
| | Streptococcal Infections | 1 | 1993 | 137 | 0.030 |
Why?
| | Thermodilution | 1 | 1991 | 13 | 0.030 |
Why?
| | Carboxyhemoglobin | 1 | 1991 | 7 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2012 | 188 | 0.030 |
Why?
| | Radioisotopes | 1 | 1991 | 35 | 0.030 |
Why?
| | Burns | 2 | 1991 | 225 | 0.030 |
Why?
| | Odds Ratio | 1 | 2014 | 1038 | 0.030 |
Why?
| | Phosphorylation | 1 | 1996 | 1678 | 0.030 |
Why?
| | Body Constitution | 1 | 1991 | 51 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 1993 | 197 | 0.030 |
Why?
| | Fetal Diseases | 2 | 2003 | 182 | 0.030 |
Why?
| | Hypertrophy, Right Ventricular | 2 | 2003 | 137 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 1996 | 1220 | 0.030 |
Why?
| | Echovirus Infections | 1 | 1990 | 1 | 0.030 |
Why?
| | Enterovirus B, Human | 1 | 1990 | 22 | 0.020 |
Why?
| | Models, Cardiovascular | 1 | 1992 | 180 | 0.020 |
Why?
| | Preoperative Period | 1 | 2010 | 103 | 0.020 |
Why?
| | Biological Transport | 1 | 1991 | 406 | 0.020 |
Why?
| | RNA, Messenger | 3 | 2007 | 2757 | 0.020 |
Why?
| | Meningoencephalitis | 1 | 1990 | 24 | 0.020 |
Why?
| | Adolescent | 6 | 2003 | 18902 | 0.020 |
Why?
| | Guanidines | 2 | 2001 | 40 | 0.020 |
Why?
| | Ultrasonography | 1 | 2015 | 784 | 0.020 |
Why?
| | Blotting, Western | 2 | 2005 | 1246 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2009 | 125 | 0.020 |
Why?
| | Hospital Costs | 1 | 2010 | 116 | 0.020 |
Why?
| | DNA | 1 | 1996 | 1363 | 0.020 |
Why?
| | Pressure | 2 | 2002 | 254 | 0.020 |
Why?
| | Constriction | 2 | 1999 | 49 | 0.020 |
Why?
| | Immunologic Techniques | 2 | 1999 | 42 | 0.020 |
Why?
| | Phenotype | 1 | 2016 | 2875 | 0.020 |
Why?
| | Heart Diseases | 1 | 1992 | 367 | 0.020 |
Why?
| | Macrophages, Alveolar | 1 | 1991 | 367 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2014 | 643 | 0.020 |
Why?
| | Receptor, Endothelin B | 2 | 2000 | 52 | 0.020 |
Why?
| | Cells, Cultured | 1 | 1996 | 4191 | 0.020 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2007 | 23 | 0.020 |
Why?
| | Heart Rate, Fetal | 2 | 1999 | 33 | 0.020 |
Why?
| | Stress, Mechanical | 2 | 1999 | 465 | 0.020 |
Why?
| | RNA, Viral | 1 | 1990 | 548 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 1072 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 1990 | 633 | 0.020 |
Why?
| | Immediate-Early Proteins | 1 | 2007 | 61 | 0.020 |
Why?
| | Protein Precursors | 2 | 2000 | 125 | 0.020 |
Why?
| | Developmental Disabilities | 1 | 2009 | 243 | 0.020 |
Why?
| | Thoracic Diseases | 1 | 2005 | 13 | 0.020 |
Why?
| | Respiratory Muscles | 1 | 2005 | 30 | 0.020 |
Why?
| | Oscillometry | 1 | 2005 | 42 | 0.020 |
Why?
| | Comorbidity | 1 | 2010 | 1650 | 0.020 |
Why?
| | Hypertrophy | 1 | 2005 | 122 | 0.020 |
Why?
| | Manometry | 1 | 2005 | 87 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2005 | 91 | 0.020 |
Why?
| | Muscular Diseases | 1 | 2005 | 106 | 0.020 |
Why?
| | Colorado | 1 | 2015 | 4401 | 0.020 |
Why?
| | Drug Combinations | 1 | 2005 | 303 | 0.020 |
Why?
| | Pulse Therapy, Drug | 1 | 2003 | 6 | 0.020 |
Why?
| | Organ Size | 1 | 2005 | 493 | 0.020 |
Why?
| | Research Design | 1 | 2010 | 968 | 0.020 |
Why?
| | Administration, Intranasal | 1 | 2003 | 86 | 0.020 |
Why?
| | Time | 1 | 2003 | 87 | 0.020 |
Why?
| | Kidney | 1 | 1991 | 1237 | 0.020 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 27 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 2007 | 496 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2002 | 67 | 0.010 |
Why?
| | Pyrroles | 1 | 2004 | 200 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2003 | 43 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 1052 | 0.010 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2002 | 69 | 0.010 |
Why?
| | Nifedipine | 1 | 2002 | 31 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2002 | 145 | 0.010 |
Why?
| | Indoles | 1 | 2004 | 332 | 0.010 |
Why?
| | Electrocardiography | 1 | 2005 | 650 | 0.010 |
Why?
| | Amidines | 1 | 2001 | 15 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2002 | 112 | 0.010 |
Why?
| | Benzylamines | 1 | 2001 | 41 | 0.010 |
Why?
| | Ligands | 1 | 2003 | 520 | 0.010 |
Why?
| | Aging | 1 | 1991 | 1690 | 0.010 |
Why?
| | Calcium Channels | 1 | 2002 | 161 | 0.010 |
Why?
| | Lung Diseases, Interstitial | 1 | 2005 | 431 | 0.010 |
Why?
| | Physical Stimulation | 1 | 2000 | 107 | 0.010 |
Why?
| | Lung Volume Measurements | 1 | 1999 | 48 | 0.010 |
Why?
| | Charybdotoxin | 1 | 1999 | 6 | 0.010 |
Why?
| | Tetraethylammonium | 1 | 1999 | 16 | 0.010 |
Why?
| | Muscle, Smooth | 1 | 2000 | 143 | 0.010 |
Why?
| | 4-Aminopyridine | 1 | 1999 | 21 | 0.010 |
Why?
| | Atrial Function, Right | 1 | 1998 | 13 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2854 | 0.010 |
Why?
| | Long-Term Care | 1 | 1998 | 70 | 0.010 |
Why?
| | Quality of Life | 1 | 2009 | 2354 | 0.010 |
Why?
| | Isothiuronium | 1 | 1998 | 4 | 0.010 |
Why?
| | Thiazines | 1 | 1998 | 8 | 0.010 |
Why?
| | Masks | 1 | 1998 | 45 | 0.010 |
Why?
| | Isoenzymes | 1 | 1999 | 320 | 0.010 |
Why?
| | Catheterization | 1 | 1998 | 168 | 0.010 |
Why?
| | Medical Records | 1 | 1998 | 175 | 0.010 |
Why?
| | Gene Expression | 1 | 2003 | 1520 | 0.010 |
Why?
| | Methylene Blue | 1 | 1996 | 25 | 0.010 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2002 | 882 | 0.010 |
Why?
| | Indomethacin | 1 | 1996 | 77 | 0.010 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 1996 | 78 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1996 | 160 | 0.010 |
Why?
| | Adenosine | 1 | 1998 | 209 | 0.010 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 1995 | 8 | 0.010 |
Why?
| | Purinones | 1 | 1995 | 4 | 0.010 |
Why?
| | Cardiomegaly | 1 | 1997 | 171 | 0.010 |
Why?
| | Purinergic P1 Receptor Antagonists | 1 | 1995 | 9 | 0.010 |
Why?
| | Adenocarcinoma, Follicular | 1 | 1995 | 31 | 0.010 |
Why?
| | Receptors, Purinergic P1 | 1 | 1995 | 29 | 0.010 |
Why?
| | Arterioles | 1 | 1995 | 48 | 0.010 |
Why?
| | Theophylline | 1 | 1995 | 58 | 0.010 |
Why?
| | Home Care Services | 1 | 1998 | 239 | 0.010 |
Why?
| | Carcinoma, Papillary | 1 | 1995 | 75 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 1999 | 1584 | 0.010 |
Why?
| | Neurotransmitter Agents | 1 | 1995 | 81 | 0.010 |
Why?
| | Renal Circulation | 1 | 1995 | 62 | 0.010 |
Why?
| | Phenylephrine | 1 | 1995 | 94 | 0.010 |
Why?
| | Adrenal Glands | 1 | 1995 | 81 | 0.010 |
Why?
| | Viper Venoms | 1 | 1994 | 10 | 0.010 |
Why?
| | Muscle Tonus | 1 | 1994 | 20 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 1995 | 456 | 0.010 |
Why?
| | Perfusion | 1 | 1994 | 167 | 0.010 |
Why?
| | Cause of Death | 1 | 1995 | 399 | 0.010 |
Why?
| | Forecasting | 1 | 1995 | 371 | 0.010 |
Why?
| | Intestines | 1 | 1995 | 320 | 0.010 |
Why?
| | Extracellular Matrix | 1 | 1995 | 422 | 0.010 |
Why?
| | Chemotaxis | 1 | 1991 | 134 | 0.010 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1990 | 26 | 0.010 |
Why?
| | Macrophage Activation | 1 | 1991 | 164 | 0.010 |
Why?
| | Agammaglobulinemia | 1 | 1990 | 33 | 0.010 |
Why?
| | Nucleic Acid Hybridization | 1 | 1990 | 192 | 0.010 |
Why?
| | Gene Amplification | 1 | 1990 | 101 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 1991 | 1143 | 0.010 |
Why?
| | Cell Count | 1 | 1990 | 323 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 1995 | 818 | 0.010 |
Why?
| | Myocardial Contraction | 1 | 1990 | 349 | 0.010 |
Why?
| | Eosinophils | 1 | 1990 | 275 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1990 | 1016 | 0.000 |
Why?
| | Monocytes | 1 | 1990 | 510 | 0.000 |
Why?
| | Skin | 1 | 1990 | 699 | 0.000 |
Why?
| | Macrophages | 1 | 1990 | 1332 | 0.000 |
Why?
|
|
Kinsella's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|